LeadArt Biotechnologies Launches the World's First Fully Automated Chemical Proteomics Sample Preparation System – 'Target Space Station'
With the advent of the post-genomic era,Proteomicshas become a core area of biomedical research. Leveraging its leading position in the field of chemical proteomics, Ningbo Leadart Biotechnology Co., Ltd. (hereinafter referred to as “Leadart”) launched in October 2023The World’s First Fully Automated Chemical Proteomics Sample Preparation System—“Target Space Station”, establishing its market leadership within the industry.This system is an innovative solution for the field of drug development, designed to accelerate the discovery of drug targets and the screening of novel ligands for these targets.
On Monday, August 19, at 19:30, the 86th edition of VCBeat’s New Product Showcase will feature Dr. Ni Feng, Founder and CEO/CTO of Leadart, and Dr. Zheng Pengfei, Associate Professor and Master’s Supervisor in the Department of Medicinal Chemistry, College of Pharmacy, Army Medical University, who will present“The World’s First Fully Automated Chemical Proteomics Sample Preparation System—Target Space Station”product promotion.
Target Space Station — Automated Drug Target Histone Preparation System
“Target Space Station” is an automated chemical proteomics sample preparation system launched by Leadart, featuring a fully automated workstation that covers the entire workflow from cell culture to drug target proteomic sample preparation.
Application Areas and Solution Pathways:“Target Space Station” integrates a fully automated workstation for cell culture and drug target proteomic sample preparation, enabling the fully automatic, high-throughput preparation of drug target proteomics samples from live cells. This technology overcomes the limitations of traditional manual proteomic sample preparation, enhances sample preparation efficiency, reduces R&D costs, and yields higher-quality big data on drug targets. By accelerating drug discovery and biomarker identification while cutting costs, it offers significant commercial value to pharmaceutical companies and research institutions.
Current Progress:Since its launch, the “Target Space Station” has attracted significant attention from numerous pharmaceutical companies and research institutions both in China and abroad. Leveraging this platform, Ningbo Leadart Biotechnology Co., Ltd. is building the world’s largest live-cell target/ligand database and has entered the commercialization phase this year. Its primary clients include leading global pharmaceutical companies and research institutions, for whom it provides services to construct drug–target databases and biomarker–probe databases.
The construction of these original, high-quality big data resources will provide robust support for the “digital-intelligence era” of new drug discovery and clinical diagnosis, driving the digital and intelligent transformation of the pharmaceutical R&D sector.
Scan the QR code on the poster to add our assistant and reserve a spot for the live broadcast.
Dr. Ni Feng
Founder, CEO/CTO of Leadart
Chemical Biology, Functional Proteomics 15+ Years of Experience
Leader of the Ningbo 3315 Innovation and Entrepreneurship Team; Vice Chairman of the Intelligent Pharmacy Professional Committee, Zhejiang Society for Bioinformatics. Has published nearly 30 influential academic papers in prestigious international journals such as JACS and Biochemistry.
He/She holds more than 20 U.S. and Chinese patents, among which the patents related to chemoproteomics and new drugs have been licensed by the University of Southern California to Bridegene (USA) for commercialization.
Dr. Zheng Pengfei
Associate Professor, Department of Medicinal Chemistry, School of Pharmacy, Army Medical University; Master’s Supervisor
My primary research focuses on the synthesis of natural product-like scaffold compounds and drug discovery targeting novel immune-metabolic pathways. I was selected for programs such as the "National Postdoctoral Innovative Talent Support Program."
Presided over more than 10 projects, including those funded by the National Natural Science Foundation of China. Published more than 20 research papers in top-tier journals in the field, such as Nature, J. Am. Chem. Soc., ACS Catal., and Eur. J. Med. Chem.; filed 3 national invention patents, with 1 granted.
About Leadart
Ningbo Leadart Biotechnology Co., Ltd., a National High-Tech Enterprise, was established in 2017. The company completed its angel round and Pre-A round of financing in 2018 and 2022, respectively, securing nearly RMB 60 million in investment from renowned venture capital firms in China and the United States. Leadart has also been honored with multiple distinctions, including inclusion in the Ningbo Overseas High-Level Entrepreneurship and Innovation Team (3315 Program), the Cixi Shanglin Talent Program, and the Ningbo Science and Technology Innovation 2025 Major Special Project, along with receiving grants totaling tens of millions of yuan.
Leadart is China’s first and one of the world’s earliest biotechnology companies based on chemical proteomics technology, as well as the world’s first company to successfully implement an automated drug discovery platform using chemical proteomics. Leadart has mastered the world’s most advanced chemical biology technologies, enabling rapid screening of early-stage novel drugs in living human cells through its proteomic “target-fishing probe” technology.
The company is committed to leading the digital transformation of new drug discovery. It has established a world-leading, automation- and digitalization-driven platform for innovative drug discovery and is currently building the largest and highest-quality database of live-cell human target/ligand interactions, with the vision of identifying ligands and active compounds for every disease-related protein target.
On the New Product Launch by VCBeat
“VCBeat New Product Launch” is a live-streaming series designed to support healthcare companies in launching their innovative products. The series aims to facilitate the milestone release of every medical innovation. Companies with plans to launch innovative medical products or achieve significant milestones and wish to participate in the “VCBeat New Product Launch” series are invited to contact our assistant for inquiries.
Method 1: Watch the live stream via Mini Program
Scan the QR code below to contact the assistant and schedule a live broadcast (if already added, please proactively reach out to the assistant).
Method 2: Watch the live stream on the VCBeat app for a chance to win lucky prizes.
Scan the QR code below to download the VCBeat app and register to watch the live stream.
Send a screenshot of the live stream to the assistant to enter the lucky draw for a chance to win a [15-day trial membership of VBInsight Industry Think Tank].
